MYND ANALYTICS, INC. (OTCMKTS:MYAN) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
At the 2017 Annual Meeting of Stockholders of MYnd Analytics, Inc. (“the Company”), held on August 21, 2017 (the “2017 Annual Meeting”), the holders of the Company’s common stock voted to elect each of the following directors to serve until the next annual meeting and until their successor is elected and qualified:
| Director | Votes For | Votes Withheld | Broker Non-Votes |
| Robin Smith, MD | 1,847,163 | 103,084 | |
| John Pappajohn | 1,847,158 | 103,084 | |
| Geoffrey Harris | 1,847,158 | 103,084 | |
| Michal Votruba | 1,847,158 | 103,084 |
At the 2017 Annual Meeting, the Company’s stockholders also voted on the following proposals:
| Proposal | For | Against | Abstain |
| To amend the Company’s 2012 Omnibus Incentive Compensation Plan (the “2012 Plan”) to increase: (i) the total number of shares of common stock available for grant under the 2012 Plan (subject to the overall limits described in clause (ii) below) from 550,000 shares to an aggregate of 975,000 shares; (ii) the aggregate limitation on authorized shares available for grant under the 2012 Plan, following any increases to the evergreen provision, from 885,781 shares to 1,570,248 shares and (iii) the annual individual award limits under the 2012 Plan to 150,000 shares of common stock (subject to adjustment in accordance with the 2012 Plan). | 1,841,899 | 5,467 | |
| To amend the Company’s certificate of incorporation (the “Charter”) to reduce the number of shares of Common Stock, authorized for issuance under the Charter from 500,000,000 to 250,000,000. | 1,949,580 | ||
| To ratify the selection by the Audit Committee of Marcum, LLP as the Company’s independent registered accounting firm for the fiscal year ending September 30, 2017. | 1,950,445 |
About MYND ANALYTICS, INC. (OTCMKTS:MYAN)
MYnd Analytics, Inc., formerly CNS Response, Inc., is a cloud-based predictive analytics company that provides objective clinical decision support to mental healthcare providers for the treatment of behavioral disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder (PTSD). It uses its neurometric platform, PEER Online, to generate Psychiatric Electroencephalogram, Evaluation Registry Reports to predict the likelihood of response by an individual to certain medications for the treatment of behavioral disorders. The Company’s technology helps in evaluating pharmacotherapy options in patients suffering from non-psychotic behavioral disorders. PEER provides medical professionals with medication sensitivity data for a subject patient based upon the identification and correlation of treatment outcome information from other patients with similar neurophysiologic characteristics. This treatment outcome information is contained in the PEER Online database.
